GlobeNewsWire
27 Oct 2025, 11:00 UTC · 47w ago
Verdict
Headline takes no side. We score AUTL +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Obecabtagene autoleucel (obe-cel) demonstrated a remission rate of 83.3% and a complete renal response of 50% in patients with severe refractory systemic lupus erythematosus (srSLE).
More positive than 99% of claims this week
Autolus has aligned with the FDA on the Phase 2 trial design and a potential registrational path to approval for obe-cel in srSLE.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 93% of claims this week
Phase 1 data showed no dose-limiting toxicities, ICANS, or Grade ≥2 cytokine release syndrome across the treated patient group.
More positive than 86% of claims this week
Autolus expects to begin dosing the first patient in the Phase 2 LUMINA clinical trial before the end of 2025.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company reported positive Phase 1 clinical data for obe-cel in treating systemic lupus erythematosus, showing durable responses and a strong safety profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
8h ago
+27.5%
Price agrees with the score
$1.95 vs $1.53 close before publication (Oct 24) · not market-adjusted
AUTL chart →
